Oncosoft today announced that it participated in ASTRO 2024 (American Society for Radiation Oncology International Conference), the world's largest radiation cancer therapy conference, held from September 29 to October 2 in Washington, D.C., USA. This was Oncosoft's first overseas booth, where its core products OncoStudio and OncoFlow were introduced.
ASTRO 2024, now in its 66th year, is a radiation therapy congress that attracts more than 10,000 radiation oncology professionals from 78 countries. OncoStudio is an artificial intelligence (AI) solution that automates CT image contouring for radiation therapy, reducing the task from three to four hours to minutes and providing greater accuracy and consistency than manual work, according to the company.
OncoStudio is targeting FDA 510(k) clearance in the first half of 2025 and will officially launch in the U.S. market that same year. Oncoflow is an integrated radiation therapy management software that manages the entire treatment process.
“ASTRO 2024 is an important starting point for Oncosoft's global expansion,” said Oncosoft. “Utilizing the latest AI technology, OncoStudio and OncoFlow will set a new standard for radiation oncology professionals around the world.”
